Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 1/2014

Open Access 01-01-2014 | Review

Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring

Authors: Li Wang, Min Yao, Zhizhen Dong, Yun Zhang, Dengfu Yao

Published in: Tumor Biology | Issue 1/2014

Login to get access

Abstract

Hepatocellular carcinoma (HCC) is one of the most common and rapidly fatal malignancies worldwide with a multifactorial, multistep, complex process and poor prognosis. Its early diagnosis and metastasis monitoring are of the utmost importance. Hepatoma tissues synthesize various tumor-related proteins, genes, enzymes, microRNA, etc. and then secrete into the blood. Detections of circulating biomarkers are useful to find tumor at an early stage or monitor metastasis after postoperative treatment. This paper summarizes recent studies of specific biomarkers at early diagnosis or in monitoring metastasis or postoperative recurrence of HCC.
Literature
1.
Yang JD, Roberts LR. Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol. 2010;7(8):449–58. PMID: 20628345.CrossRef
2.
3.
Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol. 2013;19(24):3872–82. PMID:23840128.PubMedCrossRef
4.
Wei Z, Doria C, Liu Y. Targeted therapies in the treatment of advanced hepatocellular carcinoma. Clin Med Insights Oncol. 2013;7(1):87–102. PMID: 23761989.PubMedCentralPubMedCrossRef
5.
Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res. 2010;2(1):105–18. PMID: 20182587.PubMedCentralPubMed
6.
Kawakami M, Koda M, Mandai M, Hosho K, Murawaki Y, Oda W, et al. Isolated metastases of hepatocellular carcinoma in the right atrium: case report and review of the literature. Oncol Lett. 2013;5(5):1505–8. PMID: 23760591.PubMedCentralPubMed
7.
Block TM, Marrero J, Gish RG, Sherman M, London WT, Srivastava S, et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark. 2008;4(1):19–33. PMID: 18334731.PubMed
8.
Volk ML, Hernandez JC, Su GL, Lok AS, Marrero JA. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomark. 2007;3(1):79–87. PMID: 17522429.PubMed
9.
Hayashi E, Kuramitsu Y, Okada F, Fujimoto M, Zhang X, Kobayashi M, et al. Protoemics profiling for cancer progression differential display analysis for the expression of intracellular proteins between regressive and progressive cancer cell lines. Proteomics. 2005;5(4):1024–32. PMID: 15712240.PubMedCrossRef
10.
Chen F, Xue J, Zhou L, Wu S, Chen Z. Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem. 2011;401(6):1899–904. PMID: 21833635.PubMedCentralPubMedCrossRef
11.
Wu W, Yao DF, Yuan YM, Fan JW, Lu XF, Li XH, et al. Combined serum hepatoma-specific alpha-fetoprotein and circulating alpha-fetoprotein-mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(4):538–44. PMID: 17085339.PubMed
12.
Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Prognostic relevance of oncological serum biomarkers in liver cancer patients undergoing transarterial chemoembolization therapy. Tumour Biol. 2012;33(1):33–40. PMID: 21931992.PubMedCrossRef
13.
Qu KZ, Zhang K, Li H, Afdhal NH, Albitar M. Circulating microRNAs as biomarkers for hepatocellular carcinoma. J Clin Gastroenterol. 2011;45(4):355–60. PMID: 21278583.PubMedCrossRef
14.
Wang HL, Anatelli F, Zhai QJ, Adley B, Chuang ST, Yang XJ. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions. Arch Pathol Lab Med. 2008;132(11):1723–8. PMID: 18976006.PubMed
15.
Mao YL, Yang HY, Xu HF, Sang XT, Lu X, Yang ZY, et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Chin Med J. 2008;88(14):945–51. PMID: 18756964.
16.
Hu JS, Wu DW, Liang S, Miao XY. GP73, a resident Golgi glycoprotein, is sensibility and specificity for hepatocellular carcinoma of diagnosis in a hepatitis B-endemic Asian population. Med Oncol. 2010;27(2):339–45. PMID: 19399652.PubMedCrossRef
17.
Imbeaud S, Ladeiro Y, Zucman-Rossi J. Identification of novel oncogenes and tumor suppressors in hepatocellular carcinoma. Semin Liver Dis. 2010;30(1):75–86. PMID: 20175035.PubMedCrossRef
18.
Zinkin NT, Grall F, Bhaskar K, Otu HH, Spentzos D, Kalmowitz B, et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res. 2008;14(2):470–7. PMID: 18223221.PubMedCrossRef
19.
Nouso K, Kobayashi Y, Nakamura S, Kobayashi S, Takayama H, Toshimori J, et al. Prognostic importance of fucosylated alpha-fetoprotein in hepatocellular carcinoma patients with low alpha-fetoprotein. J Gastroenterol Hepatol. 2011;26(7):1195–200. PMID: 21410750.PubMedCrossRef
20.
Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol. 2005;19(1):91–9. PMID:15757806.PubMedCrossRef
21.
Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol. 2002;20(2):305–9. PMID: 11788893.PubMed
22.
El-Serag HB, Kramer JR, Chen GJ, Duan Z, Richardson PA, Davila JA. Effectiveness of AFP and ultrasound tests on hepatocellular carcinoma mortality in HCV-infected patients in the USA. Gut. 2011;60(7):992–7. PMID: 21257990.PubMedCrossRef
23.
Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313(1):15–9. PMID: 11694234.PubMedCrossRef
24.
Kusaba T. Relationship between lens culinaris agglutinin reactive alpha-fetoprotein and biological features of hepatocellular carcinoma. Kurume Med J. 1998;45(1):113–20. PMID: 9658760.PubMedCrossRef
25.
Cheng HT, Chang YH, Chen YY, Lee TH, Tai DI, Lin DY. AFP-L3 in chronic liver diseases with persistent elevation of alpha-fetoprotein. J Chin Med Assoc. 2007;70(8):310–7. PMID: 17698430.PubMedCrossRef
26.
Miyaaki H, Nakashima O, Kurogi M, Eguchi K, Kojiro M. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol. 2007;42(12):962–8. PMID: 18085353.PubMedCrossRef
27.
Marubashi S, Nagano H, Wada H, Kobayashi S, Eguchi H, Takeda Y, et al. Clinical significance of alpha-fetoprotein mRNA in peripheral blood in liver resection for hepatocellular carcinoma. Ann Surg Oncol. 2011;18(8):2200–9. PMID: 21301972.PubMedCrossRef
28.
Zhang Y, Li Q, Liu N, Song T, Liu Z, Guo R, et al. Detection of MAGE-1, MAGE-3 and AFP mRNA as multimarker by real-time quantitative PCR assay: a possible predictor of hematogenous micrometastasis of hepatocellular carcinoma. Hepatogastroenterology. 2008;55(88):2200–6. PMID: 19260505.PubMed
29.
Montaser LM, Abbas OM, Saltah AM, Waked IA. Circulating AFP mRNA as a possible indicator of hematogenous spread of HCC cells: a possible association with HBV infection. J Egypt Natl Canc Inst. 2007;19(1):48–60. PMID: 18839035.PubMed
30.
Debruyne EN, Delanghe JR. Diagnosing and monitoring hepatocellular carcinoma with alpha-fetoprotein: new aspects and applications. Clin Chim Acta. 2008;395(1):19–26. PMID: 18538135.PubMedCrossRef
31.
Carr BI, Pancoska P, Branch RA. Significance of increased serum GGTP levels in HCC patients. Hepatogastroenterology. 2010;57(101):869–74. PMID: 21033244.PubMed
32.
Wang NY, Zhang D, Zhao W, Fang GX, Shi YL, Duan MH. Clinical application of an enzyme-linked immunosorbent assay detecting hepatoma-specific gamma-glutamyl transferase. Hepatol Res. 2009;39(10):979–87. PMID: 19624768.PubMedCrossRef
33.
Ju MJ, Qiu SJ, Fan J, Zhou J, Gao Q, Cai MY, et al. Preoperative serum gamma-glutamyl transferase to alanine aminotransferase ratio is a convenient prognostic marker for Child-Pugh A hepatocellular carcinoma after operation. J Gastroenterol. 2009;44(6):635–42. PMID: 19387533.PubMedCrossRef
34.
Morsi MI, Hussein AE, Mostafa M, El-Abd E, El-Moneim NA. Evaluation of tumour necrosis factor-alpha, soluble P-selectin, gamma-glutamyl transferase, glutathione S-transferase-pi and alpha-fetoprotein in patients with hepatocellular carcinoma before and during chemotherapy. Br J Biomed Sci. 2006;63(1):74–8. PMID: 16871999.PubMed
35.
West MB, Hanigan MH. γ-Glutamyl transpeptidase is a heavily N-glycosylated heterodimer in HepG2 cells. Arch Biochem Biophys. 2010;504(2):177–81. PMID: 20831856.PubMedCentralPubMedCrossRef
36.
Zhang JB, Chen Y, Zhang B, Xie X, Zhang L, Ge N, et al. Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol. 2011;23(9):787–93. PMID: 21730869.PubMedCrossRef
37.
Yu ZJ, Yu JW, Cai W, Yuan HX, Li XY, Yuan Y, et al. Evaluation of HCPTd1, d14-double passaged intervening chemotherapy protocol for hepatocellular carcinoma. World J Gastroenterol. 2005;11(33):5221–5. PMID: 16127757.PubMed
38.
Yao DF, Huang ZW, Chen SZ, Huang JF, Lu JX, Xiao MB, et al. Diagnosis of hepatocellular carcinoma by quantitative detection of hepatoma-specific bands of serum gamma-glutamyltransferase. Am J Clin Pathol. 1998;110(6):743–9. PMID: 9844586.PubMed
39.
Yao DF, Jiang DR, Huang ZW, Lu JX, Tao QY, Yu ZJ, et al. Abnormal expression of hepatoma specific γ-glutamyl transferase and alteration of γ-glutamyl transferase gene methylation status in patients with hepatocellular carcinoma. Cancer. 2000;88(4):761–9. PMID: 10679644.PubMedCrossRef
40.
Yao DF, Dong ZZ, Yao DB, Wu XH, Wu W, Qiu LW, et al. Abnormal expression of hepatoma-derived gamma-glutamyltransferase subtyping and its early alteration for carcinogenesis of hepatocytes. Hepatobiliary Pancreat Dis Int. 2004;3(4):564–70. PMID: 15567746.PubMed
41.
Tang QY, Yao DF, Lu JX, Wu XH, Meng XY. Expression and alterations of different molecular form gamma-glutamyl transferase and total RNA concentration during the carcinogenesis of rat hepatoma. World J Gastroenterol. 1999;5(4):356–8 [ PMID: 11819467].PubMed
42.
Filmus J, Capurro M. The role of glypican-3 in the regulation of body size and cancers. Cell Cycle. 2008;7(18):2787–90. PMID: 18787398.PubMedCrossRef
43.
Shafizadeh N, Ferrell LD, Kakar S. Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol. 2008;21(8):1011–8. PMID: 18536657.PubMedCrossRef
44.
Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, et al. Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2013;12(2):171–9. PMID: 23558072.PubMedCrossRef
45.
Nassar A, Cohen C, Siddiqui MT. Utility of glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn Cytopathol. 2009;37(9):629–35. PMID: 19405109.PubMedCrossRef
46.
Yao M, Yao DF, Bian YZ, Zhang CG, Qiu LW, Wu W, et al. Oncofetal antigen glypican-3 as a promising early diagnostic marker for hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2011;10(3):289–94. PMID: 21669573.PubMedCrossRef
47.
Yan D, He Q, Chen Y, Wang L, Zhang X. Detection of α-fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal. 2011;25(2):113–7. PMID: 21438004.PubMedCrossRef
48.
Qiao SS, Cui ZQ, Gong L, Han H, Chen PC, Guo LM, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepatogastroenterology. 2011;58(110–111):1718–24. PMID: 21940340.PubMed
49.
Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci. 2009;100(8):1403–7. PMID: 19496787.PubMedCrossRef
50.
Kandil D, Leiman G, Allegretta M, Trotman W, Pantanowitz L, Goulart R, et al. Glypican-3 immunocytochemistry in liver fine-needle aspirates: a novel stain to assist in the differentiation of benign and malignant liver lesions. Cancer. 2007;111(5):316–22. PMID: 17763368.PubMedCrossRef
51.
52.
Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor beta in human disease. N Engl J Med. 2000;342(18):1350–8. PMID: 10793168.PubMedCrossRef
53.
Bissell DM, Roulot D, George J. Transforming growth factor beta and the liver. Hepatology. 2001;34(5):859–67. PMID: 11679955.PubMedCrossRef
54.
Lee D, Chung YH, Kim JA, Lee YS, Lee D, Jang MK, et al. Transforming growth factor beta 1 overexpression is closely related to invasiveness of hepatocellular carcinoma. Oncology. 2012;82(1):11–8. PMID: 22269311.PubMedCrossRef
55.
Divella R, Daniele A, Gadaleta C, Tufaro A, Venneri MT, Paradiso A, et al. Circulating transforming growth factor-β and epidermal growth factor receptor as related to virus infection in liver carcinogenesis. Anticancer Res. 2012;32(1):141–5. PMID: 22213299.PubMed
56.
Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, Grady WM. Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology. 2012;55(1):121–31. PMID: 21898503.PubMedCentralPubMedCrossRef
57.
Yamazaki K, Masugi Y, Sakamoto M. Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis. 2011;29(3):284–8. PMID: 21829019.PubMedCrossRef
58.
Hoshida Y. Molecular signatures and prognosis of hepatocellular carcinoma. Minerva Gastroenterol Dietol. 2011;57(3):311–22. PMID:21769080.PubMed
59.
Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2008;7(3):288–95. PMID: 18522884.PubMed
60.
Dong ZZ, Yao DF, Zou L, Yao M, Qiu LW, Wu XH, et al. An evaluation of transforming growth factor-beta 1 in diagnosing hepatocellular carcinoma and metastasis. Zhonghua Gan Zang Bing Za Zhi. 2007;15(7):503–8. Chinese [PMID: 17669238].PubMed
61.
Scharf JG, Braulke T. The role of the IGF axis in hepatocarcinogenesis. Horm Metab Res. 2003;35(11–12):685–93. PMID: 14710347.PubMed
62.
Rehem RN, El-Shikh WM. Serum IGF-1, IGF-2 and IGFBP-3 as parameters in the assessment of liver dysfunction in patients with hepatic cirrhosis and in the diagnosis of hepatocellular carcinoma. Hepatogastroenterology. 2011;58(108–108):949–54. PMID: 21830422.PubMed
63.
Cantarini MC, de la Monte SM, Pang M, Tong M, D'Errico A, Trevisani F, et al. Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology. 2006;44(2):446–57. PMID: 16871543.PubMedCrossRef
64.
Wang Z, Ruan YB, Guan Y, Liu SH. Expression of IGF-II in early experimental hepatocellular carcinomas and its significance in early diagnosis. World J Gastroenterol. 2003;9(2):267–70. PMID: 12532445.PubMed
65.
Qiu LW, Yao DF, Zong L, Lu YY, Huang H, Wu W, et al. Abnormal expression of insulin-like growth factor-II and its dynamic quantitative analysis at different stages of hepatocellular carcinoma development. Hepatobiliary Pancreat Dis Int. 2008;7(4):406–11. PMID: 18693177.PubMed
66.
Dong ZZ, Yao DF, Yao DB, Wu XH, Wu W, Qiu LW, et al. Expression and alteration of insulin-like growth factor II-messenger RNA in hepatoma tissues and peripheral blood of patients with hepatocellular carcinoma. World J Gastroenterol. 2005;11(30):4655–60. PMID: 16094705.PubMed
67.
Yao DF, Dong ZZ, Liu YH, Zhao L, Huang JF, Meng XY. Amplification of peripheral blood insulin-like growth factor II-mRNA and its clinical significance in the diagnosis of hepatocellular carcinoma. Zhonghua Gan Zang Bing Za Zhi. 2003;11(11):695–6. Chinese [PMID: 14636457].PubMed
68.
Qian J, Yao D, Dong Z, Wu W, Qiu L, Yao N, et al. Characteristics of hepatic IGF-II expression and monitored levels of circulating IGF-II mRNA in metastasis of hepatocellular carcinoma. Am J Clin Pathol. 2010;134(5):799–806. PMID: 20959664.PubMedCrossRef
69.
Dong ZZ, Yao DF, Wu XH, Shi GS, Qiu LW, Wu W, et al. Early diagnostic value of abnormal expression of insulin-like growth factor (IGF)-II and IGF-II mRNA in hepatocellular carcinoma patients. Zhonghua Gan Zang Bing Za Zhi. 2005;13(11):866–8. Chinese [PMID: 16313745].PubMed
70.
71.
Satyanarayana A, Manns MP, Rudolph KL. Telomeres and telomerase: a dual role in hepatocarcinogenesis. Hepatology. 2004;40(2):276–83. PMID: 15368430.PubMedCrossRef
72.
73.
74.
Lewis KA, Wuttke DS. Telomerase and telomere-associated proteins: structural insights into mechanism and evolution. Structure. 2012;20(1):28–39. PMID: 22244753.PubMedCrossRef
75.
Yao DF, Wu W, Yao M, Qiu LW, Wu XH, Su XQ, et al. Dynamic alteration of telomerase expression and its diagnostic significance in liver or peripheral blood for hepatocellular carcinoma. World J Gastroenterol. 2006;12(31):4966–72. PMID:16937491.PubMed
76.
Wu W, Yao DF, Qiu LW, Wu XH, Yao M, Su XQ, et al. Abnormal expression of hepatomas and circulating telomerase and its clinical values. Hepatobiliary Pancreat Dis Int. 2005;4(4):544–9. PMID: 16286259.PubMed
77.
Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005;10(2):86–103. PMID: 16038406.PubMedCentralPubMedCrossRef
78.
Lu WJ, Lee NP, Fatima S, Luk JM. Heat shock proteins in cancer: signaling pathways, tumor markers and molecular targets in liver malignancy. Protein Pept Lett. 2009;16(5):508–16. PMID: 19442230.PubMedCrossRef
79.
Sakamoto M, Mori T, Masugi Y, Effendi K, Rie I, Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology. 2008;51(1):42–5. PMID: 18544947.PubMedCrossRef
80.
Wu XH, Yao DF, Su XQ, Tai BJ, Huang H, Qiu LW, et al. Dynamic expression of rat heat shock protein gp96 and its gene during development of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2007;6(6):616–21. PMID: 18086628.PubMed
81.
Yao DF, Wu XH, Su XQ, Yao M, Wu W, Qiu LW, et al. Abnormal expression of HSP gp96 associated with HBV replication in human hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2006;5(3):381–6. PMID: 16911935.PubMed
82.
Luk JM, Lam CT, Siu AF, Lam BY, Ng IO, Hu MY, et al. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics. 2006;6(3):1049–57. PMID: 16400691.PubMedCrossRef
83.
84.
Kojima K, Takata A, Vadnais C, Otsuka M, Yoshikawa T, Akanuma M, et al. MicroRNA122 is a key regulator of α-fetoprotein expression and influences the aggressiveness of hepatocellular carcinoma. Nat Commun. 2011;2(2):338. PMID: 21654638.PubMedCrossRef
85.
Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a potential marker for detecting liver pathologies. Clin Sci. 2011;120(5):183–93. PMID: 20815808.PubMedCentralPubMedCrossRef
86.
Effendi K, Sakamoto M. Molecular pathology in early hepatocarcinogenesis. Oncology. 2010;78(2):157–60. PMID: 20389138.PubMedCrossRef
87.
Augello C, Vaira V, Caruso L, Destro A, Maggioni M, Park YN, et al. MicroRNA profiling of hepatocarcinogenesis identifies C19MC cluster as a novel prognostic biomarker in hepatocellular carcinoma. Liver Int. 2012;32(5):772–82. PMID: 22429613.PubMedCrossRef
88.
Giordano S, Columbano A. MicroRNAs: new tools for diagnosis, prognosis, and therapy in hepatocellular carcinoma? Hepatology. 2013;57(2):840–7. PMID: 23081718.PubMedCrossRef
89.
Zhao X, Yang Z, Li G, Li D, Zhao Y, Wu Y, et al. The role and clinical implications of microRNAs in hepatocellular carcinoma. Sci China Life Sci. 2012;55(10):906–19. PMID: 23108868.PubMedCrossRef
90.
Liao SF, Yang HI, Lee MH, Chen CJ, Lee WC. Fifteen-year population attributable fractions and causal pies of risk factors for newly developed hepatocellular carcinomas in 11,801 men in Taiwan. PLoS One. 2012;7(4):e34779. PMID: 22506050.PubMedCentralPubMedCrossRef
91.
Gish RG, Lencioni R, Di Bisceglie AM, Raoul JL, Mazzaferro V. Role of the multi-disciplinary team in the diagnosis and treatment of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol. 2012;6(2):173–85. PMID: 22375523.PubMedCrossRef
92.
Wong VW, Chan HL. Prevention of hepatocellular carcinoma: a concise review of contemporary issues. Ann Hepatol. 2012;11(3):284–93. PMID: 22481445.PubMed
93.
Abdalla MA, Haj-Ahmad Y. Promising candidate urinary MicroRNA biomarkers for the early detection of hepatocellular carcinoma among high-risk hepatitis C virus Egyptian patients. J Cancer. 2012;3(1):19–31. PMID: 22211142.PubMedCentralPubMedCrossRef
94.
Kohles N, Nagel D, Jüngst D, Durner J, Stieber P, Holdenrieder S. Relevance of circulating nucleosomes and oncological biomarkers for predicting response to transarterial chemoembolization therapy in liver cancer patients. BMC Cancer. 2011;11(1):202. PMID: 21615953.PubMedCentralPubMedCrossRef
95.
Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S, et al. Highly sensitive lens culinaris agglutinin-reactive α-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep. 2011;26(5):1227–33. PMID: 21874252.PubMed
96.
Petrelli A, Perra A, Schernhuber K, Cargnelutti M, Salvi A, Migliore C, et al. Sequential analysis of multistage hepatocarcinogenesis reveals that miR-100 and PLK1 dysregulation is an early event maintained along tumor progression. Oncogene. 2012;31(42):4517–26. PMID: 22249248.PubMedCrossRef
Metadata
Title
Circulating specific biomarkers in diagnosis of hepatocellular carcinoma and its metastasis monitoring
Authors
Li Wang
Min Yao
Zhizhen Dong
Yun Zhang
Dengfu Yao
Publication date
01-01-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1141-0

Other articles of this Issue 1/2014

Tumor Biology 1/2014 Go to the issue

Research Article

Downregulation of microRNA-182 inhibits cell growth and invasion by targeting programmed cell death 4 in human lung adenocarcinoma cells

Research Article

RETRACTED ARTICLE: Association between single-nucleotide polymorphisms of OGG1 gene and pancreatic cancer risk in Chinese Han population

Research Article

Prognostic significance of sphingosine kinase 2 expression in non-small cell lung cancer

Review

The circadian clock and the hypoxic response pathway in kidney cancer

Research Article

Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial–mesenchymal transition biomarkers

Research Article

Association of the interleukin-4Rα rs1801275 and rs1805015 polymorphisms with glioma risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits